Clinical Trials Logo

Clinical Trial Summary

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05295875
Study type Interventional
Source Altimmune, Inc.
Contact
Status Completed
Phase Phase 2
Start date March 31, 2022
Completion date September 28, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04599478 - Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) Phase 2/Phase 3
Enrolling by invitation NCT04599504 - Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) Phase 2/Phase 3
Enrolling by invitation NCT04605081 - Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) Phase 2/Phase 3